Compare PROF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | MXCT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 186.7M |
| IPO Year | N/A | 2021 |
| Metric | PROF | MXCT |
|---|---|---|
| Price | $6.60 | $1.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $11.00 | $7.50 |
| AVG Volume (30 Days) | 100.8K | ★ 1.5M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,297,000.00 | ★ $34,419,000.00 |
| Revenue This Year | $64.23 | N/A |
| Revenue Next Year | $113.06 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.94 | N/A |
| 52 Week Low | $3.76 | $1.26 |
| 52 Week High | $8.36 | $5.20 |
| Indicator | PROF | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 41.45 |
| Support Level | $6.09 | $1.45 |
| Resistance Level | $7.04 | $1.80 |
| Average True Range (ATR) | 0.42 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 70.27 | 14.42 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.